"Pfizer and BioNTech today announced that they have begun evaluating the safety and immunogenicity of the third dose of COVID-19 vaccine BNT162b2 to determine the effect of the COVID-19 immunity booster caused by already circulating and potentially new variants of SARS-CoV-2," the press said. -release of an American company.
Manufacturers hope that the new study will help evaluate the effectiveness of the vaccine against new mutations in the coronavirus.
The tests will involve at least 144 participants in two age groups - from 18 to 55 years and from 65 to 85.
Their condition will be assessed directly at the time of receiving the third dose of the vaccine, one week and one month after vaccination, and then for two years.
At the end of December, the European Medicines Agency authorized the use of the COVID-19 vaccine Pfizer and BioNTech in the EU for people over 16 years old.
Manufacturers have claimed 95% effectiveness for their coronavirus vaccine.